Senior researcher of pharmaceutical chemistry

GuangDong NewOpp Biopharmaceuticals Co., Ltd. is an innovative anti-tumor drug R & D enterprise founded by biologists and chemists from Novartis, Merck, etc. the core team members have the successful experience of leading the development of a number of small molecule innovative drugs and achieving the listing.

The founder and chief biologist is a doctor of molecular biology of New York University. He once served as technical director and deputy director of cancer center of Institute of genomics (GNF) of Novartis pharmaceutical research foundation. In 2018, he was selected into the national major talent introduction project. He has published 24 papers in nature, science, cell and other international journals, with 380 influencing factors, and has been cited more than 7770 times by others. In the GNF cancer center of Novartis, he has developed the anti-small cell lung cancer drug seretinib and the anti melanoma drug corneafinil.
Co founder and chief chemist of the Department of education of the Ministry of education, the first batch of graduate students studying in the United States in the China US chemical postgraduate training program (CGP), and a Ph.D. in organic synthetic chemistry from Yale University. Focusing on the research and development of small molecule new drugs, he has published 57 professional papers and obtained more than 60 invention patents. He is a senior member of the American Chemical Society and other academic organizations. He was a senior scientist and chief pharmacist of Merck pharmaceutical R & D center in Canada. He led and participated in the research and development of three new drugs, Vioxx, and other anti-inflammatory and analgesic drugs. He has led the research and development of anti-tumor drugs EP4 antagonists and IDO inhibitors in China, and transferred the development rights and interests by milestone way of US $100 million and US $457 million respectively.

The company has a registered capital of 100 million yuan, a start-up capital of 50 million yuan, and nearly 30 million yuan of government support. It has been focused by many professional investment institutions in the field of biomedicine. In 2019, the founder was rated as outstanding talent of Huangpu District, and the leadership team was selected into the project of entrepreneurial talent plan of Huangpu District in the same year. In 2020, the company was selected into the Pearl River talent plan innovation and entrepreneurship team of Guangdong Province.

Taking root in Huangpu District of Guangzhou, the company adheres to the principle of focus on the future and love the world, adheres to the original innovation (first in class) and best in class (best in class). With the goal of new target selection and new drug development, the company is committed to the research and development of specific and efficient anti-tumor drugs for individualized treatment, precision medicine and immunotherapy, so as to provide specific and effective drug treatment for cancer patients. The company has rich product pipelines and many R & D projects are in the international leading position.
The core team of the company has rich practical experience in scientific research, and strategic planning selects and cultivates its own R & D team in the global pharmaceutical industry. We sincerely welcome you to join us, and you will have a great harvest here!

Be responsible for the work of drug R & D laboratory and assist in management.